Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA AMPLIFICATION
(
ENST00000263967.4 )
PIK3CA AMPLIFICATION ( ENST00000263967.4, ENST00000497599.5 ) - Associated Disease
- stomach carcinoma
- Source Database
- CIViC Evidence
- Description
- 474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1403
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/212
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Stomach Carcinoma
- Evidence Direction
- Supports
- Drug
- Alpelisib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24608574
Drugs
Drug Name | Sensitivity | Supported |
---|---|---|
Alpelisib | Sensitivity | true |